APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell and Gene Therapy (CGT) Logistic

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cell and Gene Therapy (CGT) Logistic Market Analysis and Forecast 2026-2032

3 May 2026213 pages

Choose your research edition.

Industry ResearchCell and Gene Therapy (CGT) Logistic Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell and Gene Therapy (CGT) Logistic Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Cell and Gene Therapy (CGT) Logistic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell and Gene Therapy (CGT) Logistic Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell and Gene Therapy (CGT) Logistic Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Cell and Gene Therapy (CGT) Logistic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cell and Gene Therapy (CGT) Logistic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cell and Gene Therapy (CGT) Logistic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cell and Gene Therapy (CGT) Logistic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cell and Gene Therapy (CGT) Logistic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cell and Gene Therapy (CGT) Logistic include Cencora, Inc（World Courier）, QuickStat, Associated Couriers, LLC, Central Pharma, POLAR EXPRES, Biocair, time:matters, Mercury Business Services and Cardinal Health, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cell and Gene Therapy (CGT) Logistic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cell and Gene Therapy (CGT) Logistic, also provides the revenue of main regions and countries. Of the upcoming market potential for Cell and Gene Therapy (CGT) Logistic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cell and Gene Therapy (CGT) Logistic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cell and Gene Therapy (CGT) Logistic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cell and Gene Therapy (CGT) Logistic revenue, projected growth trends, production technology, application and end-user industry.

Cell and Gene Therapy (CGT) Logistic Segment by Company

Cencora, Inc（World Courier）

QuickStat

Associated Couriers, LLC

Central Pharma

POLAR EXPRES

Biocair

time:matters

Mercury Business Services

Cardinal Health

CRYOPDP

Cryoport

NMDP BioTherapies

McKesson

Excel Courier

Almac

BEAM Logistics

Cell and Gene Therapy (CGT) Logistic Segment by Type

National Transportation

International Transportation

Cell and Gene Therapy (CGT) Logistic Segment by Application

Biotech and Pharmaceutical Companies

Hospitals

Research Organizations

Other

Cell and Gene Therapy (CGT) Logistic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy (CGT) Logistic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy (CGT) Logistic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy (CGT) Logistic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cell and Gene Therapy (CGT) Logistic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cell and Gene Therapy (CGT) Logistic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell and Gene Therapy (CGT) Logistic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cell and Gene Therapy (CGT) Logistic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. National Transportation Major Player Table 3. International Transportation Major Player Table 4. Global Cell and Gene Therapy (CGT) Logistic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Biotech and Pharmaceutical Companies Major Player Table 6. Hospitals Major Player Table 7. Research Organizations Major Player Table 8. Other Major Player Table 9. Cell and Gene Therapy (CGT) Logistic Industry Trends Table 10. Cell and Gene Therapy (CGT) Logistic Industry Drivers Table 11. Cell and Gene Therapy (CGT) Logistic Industry Opportunities and Challenges Table 12. Cell and Gene Therapy (CGT) Logistic Industry Restraints Table 13. Global Cell and Gene Therapy (CGT) Logistic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Cell and Gene Therapy (CGT) Logistic Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Cell and Gene Therapy (CGT) Logistic Market Share by Region (2021-2026) Table 16. Global Cell and Gene Therapy (CGT) Logistic Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Cell and Gene Therapy (CGT) Logistic Market Share by Region (2027-2032) Table 18. Global Cell and Gene Therapy (CGT) Logistic Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Players (2021-2026) Table 20. Global Cell and Gene Therapy (CGT) Logistic Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Cell and Gene Therapy (CGT) Logistic Key Players Headquarters & Area Served Table 22. Global Cell and Gene Therapy (CGT) Logistic Players, Product Type & Application Table 23. Global Cell and Gene Therapy (CGT) Logistic Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Cell and Gene Therapy (CGT) Logistic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Cell and Gene Therapy (CGT) Logistic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Type (2021-2026) Table 30. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Type (2027-2032) Table 31. Global Cell and Gene Therapy (CGT) Logistic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Application (2021-2026) Table 35. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Application (2027-2032) Table 36. Cencora, Inc（World Courier） Company Information Table 37. Cencora, Inc（World Courier） Business Overview Table 38. Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 40. Cencora, Inc（World Courier） Recent Development Table 41. QuickStat Company Information Table 42. QuickStat Business Overview Table 43. QuickStat Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. QuickStat Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 45. QuickStat Recent Development Table 46. Associated Couriers, LLC Company Information Table 47. Associated Couriers, LLC Business Overview Table 48. Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 50. Associated Couriers, LLC Recent Development Table 51. Central Pharma Company Information Table 52. Central Pharma Business Overview Table 53. Central Pharma Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Central Pharma Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 55. Central Pharma Recent Development Table 56. POLAR EXPRES Company Information Table 57. POLAR EXPRES Business Overview Table 58. POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 60. POLAR EXPRES Recent Development Table 61. Biocair Company Information Table 62. Biocair Business Overview Table 63. Biocair Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Biocair Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 65. Biocair Recent Development Table 66. time:matters Company Information Table 67. time:matters Business Overview Table 68. time:matters Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. time:matters Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 70. time:matters Recent Development Table 71. Mercury Business Services Company Information Table 72. Mercury Business Services Business Overview Table 73. Mercury Business Services Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Mercury Business Services Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 75. Mercury Business Services Recent Development Table 76. Cardinal Health Company Information Table 77. Cardinal Health Business Overview Table 78. Cardinal Health Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Cardinal Health Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 80. Cardinal Health Recent Development Table 81. CRYOPDP Company Information Table 82. CRYOPDP Business Overview Table 83. CRYOPDP Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. CRYOPDP Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 85. CRYOPDP Recent Development Table 86. Cryoport Company Information Table 87. Cryoport Business Overview Table 88. Cryoport Cell and Gene Therapy (CGT) Logistic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Cryoport Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 90. Cryoport Recent Development Table 91. NMDP BioTherapies Company Information Table 92. NMDP BioTherapies Business Overview Table 93. NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 95. NMDP BioTherapies Recent Development Table 96. McKesson Company Information Table 97. McKesson Business Overview Table 98. McKesson Cell and Gene Therapy (CGT) Logistic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. McKesson Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 100. McKesson Recent Development Table 101. Excel Courier Company Information Table 102. Excel Courier Business Overview Table 103. Excel Courier Cell and Gene Therapy (CGT) Logistic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Excel Courier Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 105. Excel Courier Recent Development Table 106. Almac Company Information Table 107. Almac Business Overview Table 108. Almac Cell and Gene Therapy (CGT) Logistic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Almac Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 110. Almac Recent Development Table 111. BEAM Logistics Company Information Table 112. BEAM Logistics Business Overview Table 113. BEAM Logistics Cell and Gene Therapy (CGT) Logistic Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. BEAM Logistics Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 115. BEAM Logistics Recent Development Table 116. North America Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Cell and Gene Therapy (CGT) Logistic Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country (US$ Million) & (2027-2032) Table 130. China Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026) & (US$ Million) Table 131. China Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032) & (US$ Million) Table 132. China Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026) & (US$ Million) Table 133. China Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Cell and Gene Therapy (CGT) Logistic Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Cell and Gene Therapy (CGT) Logistic Image Figure 2. Global Cell and Gene Therapy (CGT) Logistic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell and Gene Therapy (CGT) Logistic Market Size Share 2021 VS 2025 VS 2032 Figure 4. National Transportation Image Figure 5. International Transportation Image Figure 6. Global Cell and Gene Therapy (CGT) Logistic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Cell and Gene Therapy (CGT) Logistic Market Size Share 2021 VS 2025 VS 2032 Figure 8. Biotech and Pharmaceutical Companies Image Figure 9. Hospitals Image Figure 10. Research Organizations Image Figure 11. Other Image Figure 12. Global Cell and Gene Therapy (CGT) Logistic Market Size (US$ Million) & (2021-2032) Figure 13. Global Cell and Gene Therapy (CGT) Logistic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Cell and Gene Therapy (CGT) Logistic Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Cell and Gene Therapy (CGT) Logistic Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Type (2021-2032) Figure 20. Global Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Application (2021-2032) Figure 23. North America Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032) Figure 25. North America Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032) Figure 26. North America Cell and Gene Therapy (CGT) Logistic Revenue Share by Country (2021-2032) Figure 27. United States Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032) Figure 32. Europe Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032) Figure 33. Europe Cell and Gene Therapy (CGT) Logistic Revenue Share by Country (2021-2032) Figure 34. Germany Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032) Figure 44. China Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032) Figure 45. Asia Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032) Figure 47. Asia Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032) Figure 48. Asia Cell and Gene Therapy (CGT) Logistic Revenue Share by Region (2021-2032) Figure 49. Japan Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032) Figure 57. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032) Figure 58. SAMEA Cell and Gene Therapy (CGT) Logistic Revenue Share by Country (2021-2032) Figure 59. Brazil Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Cell and Gene Therapy (CGT) Logistic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • National Transportation
  • International Transportation
Applications
  • Biotech and Pharmaceutical Companies
  • Hospitals
  • Research Organizations
  • Other
Companies covered
  • Cencora, Inc（World Courier）
  • QuickStat
  • Associated Couriers, LLC
  • Central Pharma
  • POLAR EXPRES
  • Biocair
  • time:matters
  • Mercury Business Services
  • Cardinal Health
  • CRYOPDP
  • Cryoport
  • NMDP BioTherapies
  • McKesson
  • Excel Courier
  • Almac
  • BEAM Logistics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cell and Gene Therapy (CGT) Logistic Market by Type
  3. 1.2.1 Global Cell and Gene Therapy (CGT) Logistic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 National Transportation
  5. 1.2.3 International Transportation
  6. 1.3 Cell and Gene Therapy (CGT) Logistic Market by Application
  7. 1.3.1 Global Cell and Gene Therapy (CGT) Logistic Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Biotech and Pharmaceutical Companies
  9. 1.3.3 Hospitals
  10. 1.3.4 Research Organizations
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Cell and Gene Therapy (CGT) Logistic Market Dynamics
  1. 2.1 Cell and Gene Therapy (CGT) Logistic Industry Trends
  2. 2.2 Cell and Gene Therapy (CGT) Logistic Industry Drivers
  3. 2.3 Cell and Gene Therapy (CGT) Logistic Industry Opportunities and Challenges
  4. 2.4 Cell and Gene Therapy (CGT) Logistic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cell and Gene Therapy (CGT) Logistic Market Perspective (2021-2032)
  2. 3.2 Global Cell and Gene Therapy (CGT) Logistic Growth Trends by Region
  3. 3.2.1 Global Cell and Gene Therapy (CGT) Logistic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cell and Gene Therapy (CGT) Logistic Market Size by Region (2021-2026)
  5. 3.2.3 Global Cell and Gene Therapy (CGT) Logistic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cell and Gene Therapy (CGT) Logistic Revenue by Players
  2. 4.1.1 Global Cell and Gene Therapy (CGT) Logistic Revenue by Players (2021-2026)
  3. 4.1.2 Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cell and Gene Therapy (CGT) Logistic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cell and Gene Therapy (CGT) Logistic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cell and Gene Therapy (CGT) Logistic Key Players Headquarters & Area Served
  7. 4.4 Global Cell and Gene Therapy (CGT) Logistic Players, Product Type & Application
  8. 4.5 Global Cell and Gene Therapy (CGT) Logistic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cell and Gene Therapy (CGT) Logistic Market CR5 and HHI
  11. 4.6.3 2025 Cell and Gene Therapy (CGT) Logistic Tier 1, Tier 2, and Tier 3
5 Cell and Gene Therapy (CGT) Logistic Market Size by Type
  1. 5.1 Global Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2032)
  3. 5.3 Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Type (2021-2032)
6 Cell and Gene Therapy (CGT) Logistic Market Size by Application
  1. 6.1 Global Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2032)
  3. 6.3 Global Cell and Gene Therapy (CGT) Logistic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cencora, Inc（World Courier）
  2. 7.1.1 Cencora, Inc（World Courier） Company Information
  3. 7.1.2 Cencora, Inc（World Courier） Business Overview
  4. 7.1.3 Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Product Portfolio
  6. 7.1.5 Cencora, Inc（World Courier） Recent Developments
  7. 7.2 QuickStat
  8. 7.2.1 QuickStat Company Information
  9. 7.2.2 QuickStat Business Overview
  10. 7.2.3 QuickStat Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 QuickStat Cell and Gene Therapy (CGT) Logistic Product Portfolio
  12. 7.2.5 QuickStat Recent Developments
  13. 7.3 Associated Couriers, LLC
  14. 7.3.1 Associated Couriers, LLC Company Information
  15. 7.3.2 Associated Couriers, LLC Business Overview
  16. 7.3.3 Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Product Portfolio
  18. 7.3.5 Associated Couriers, LLC Recent Developments
  19. 7.4 Central Pharma
  20. 7.4.1 Central Pharma Company Information
  21. 7.4.2 Central Pharma Business Overview
  22. 7.4.3 Central Pharma Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Central Pharma Cell and Gene Therapy (CGT) Logistic Product Portfolio
  24. 7.4.5 Central Pharma Recent Developments
  25. 7.5 POLAR EXPRES
  26. 7.5.1 POLAR EXPRES Company Information
  27. 7.5.2 POLAR EXPRES Business Overview
  28. 7.5.3 POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Product Portfolio
  30. 7.5.5 POLAR EXPRES Recent Developments
  31. 7.6 Biocair
  32. 7.6.1 Biocair Company Information
  33. 7.6.2 Biocair Business Overview
  34. 7.6.3 Biocair Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Biocair Cell and Gene Therapy (CGT) Logistic Product Portfolio
  36. 7.6.5 Biocair Recent Developments
  37. 7.7 time:matters
  38. 7.7.1 time:matters Company Information
  39. 7.7.2 time:matters Business Overview
  40. 7.7.3 time:matters Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  41. 7.7.4 time:matters Cell and Gene Therapy (CGT) Logistic Product Portfolio
  42. 7.7.5 time:matters Recent Developments
  43. 7.8 Mercury Business Services
  44. 7.8.1 Mercury Business Services Company Information
  45. 7.8.2 Mercury Business Services Business Overview
  46. 7.8.3 Mercury Business Services Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Mercury Business Services Cell and Gene Therapy (CGT) Logistic Product Portfolio
  48. 7.8.5 Mercury Business Services Recent Developments
  49. 7.9 Cardinal Health
  50. 7.9.1 Cardinal Health Company Information
  51. 7.9.2 Cardinal Health Business Overview
  52. 7.9.3 Cardinal Health Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Cardinal Health Cell and Gene Therapy (CGT) Logistic Product Portfolio
  54. 7.9.5 Cardinal Health Recent Developments
  55. 7.10 CRYOPDP
  56. 7.10.1 CRYOPDP Company Information
  57. 7.10.2 CRYOPDP Business Overview
  58. 7.10.3 CRYOPDP Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  59. 7.10.4 CRYOPDP Cell and Gene Therapy (CGT) Logistic Product Portfolio
  60. 7.10.5 CRYOPDP Recent Developments
  61. 7.11 Cryoport
  62. 7.11.1 Cryoport Company Information
  63. 7.11.2 Cryoport Business Overview
  64. 7.11.3 Cryoport Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Cryoport Cell and Gene Therapy (CGT) Logistic Product Portfolio
  66. 7.11.5 Cryoport Recent Developments
  67. 7.12 NMDP BioTherapies
  68. 7.12.1 NMDP BioTherapies Company Information
  69. 7.12.2 NMDP BioTherapies Business Overview
  70. 7.12.3 NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  71. 7.12.4 NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Product Portfolio
  72. 7.12.5 NMDP BioTherapies Recent Developments
  73. 7.13 McKesson
  74. 7.13.1 McKesson Company Information
  75. 7.13.2 McKesson Business Overview
  76. 7.13.3 McKesson Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  77. 7.13.4 McKesson Cell and Gene Therapy (CGT) Logistic Product Portfolio
  78. 7.13.5 McKesson Recent Developments
  79. 7.14 Excel Courier
  80. 7.14.1 Excel Courier Company Information
  81. 7.14.2 Excel Courier Business Overview
  82. 7.14.3 Excel Courier Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Excel Courier Cell and Gene Therapy (CGT) Logistic Product Portfolio
  84. 7.14.5 Excel Courier Recent Developments
  85. 7.15 Almac
  86. 7.15.1 Almac Company Information
  87. 7.15.2 Almac Business Overview
  88. 7.15.3 Almac Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Almac Cell and Gene Therapy (CGT) Logistic Product Portfolio
  90. 7.15.5 Almac Recent Developments
  91. 7.16 BEAM Logistics
  92. 7.16.1 BEAM Logistics Company Information
  93. 7.16.2 BEAM Logistics Business Overview
  94. 7.16.3 BEAM Logistics Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BEAM Logistics Cell and Gene Therapy (CGT) Logistic Product Portfolio
  96. 7.16.5 BEAM Logistics Recent Developments
8 North America
  1. 8.1 North America Cell and Gene Therapy (CGT) Logistic Revenue (2021-2032)
  2. 8.2 North America Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2032)
  3. 8.2.1 North America Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026)
  4. 8.2.2 North America Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032)
  5. 8.3 North America Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032)
  6. 8.4 North America Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2032)
  7. 8.4.1 North America Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026)
  8. 8.4.2 North America Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032)
  9. 8.5 North America Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032)
  10. 8.6 North America Cell and Gene Therapy (CGT) Logistic Revenue by Country
  11. 8.6.1 North America Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026)
  13. 8.6.3 North America Cell and Gene Therapy (CGT) Logistic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cell and Gene Therapy (CGT) Logistic Revenue (2021-2032)
  2. 9.2 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032)
  5. 9.3 Europe Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032)
  9. 9.5 Europe Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country
  11. 9.6.1 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cell and Gene Therapy (CGT) Logistic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cell and Gene Therapy (CGT) Logistic Revenue (2021-2032)
  2. 10.2 China Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2032)
  3. 10.2.1 China Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026)
  4. 10.2.2 China Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032)
  5. 10.3 China Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032)
  6. 10.4 China Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2032)
  7. 10.4.1 China Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026)
  8. 10.4.2 China Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032)
  9. 10.5 China Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cell and Gene Therapy (CGT) Logistic Revenue (2021-2032)
  2. 11.2 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032)
  5. 11.3 Asia Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032)
  9. 11.5 Asia Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Country
  11. 11.6.1 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cell and Gene Therapy (CGT) Logistic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue (2021-2032)
  2. 12.2 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country
  11. 12.6.1 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cell and Gene Therapy (CGT) Logistic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst